Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Miscellaneous

The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or
the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601
monotherapy and in combination with gemcitabine.
Miscellaneous
I
Davis, Elizabeth
NCT05389462
VICCPHI2225

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Lymphoma

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and
expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in
combination with standard of care options for the treatment of rrDLBCL. This study will be
divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will
enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in
combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) is superior to R-GemOx
with respect to progression-free survival (PFS) per Lugano response criteria by blinded
independent review committee (BICR); and that ZV in combination with bendamustine rituximab
(BR) is superior to BR with respect to PFS per Lugano response criteria by BICR.
Lymphoma
II/III
Baljevic, Muhamed
NCT05139017
VICCPCL2228

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.